Co-designing an intervention to improve the process of deprescribing for older people living with frailty in the United Kingdom.
aged
deprescribing
frailty
polypharmacy
primary health care
referral and consultation
Journal
Health expectations : an international journal of public participation in health care and health policy
ISSN: 1369-7625
Titre abrégé: Health Expect
Pays: England
ID NLM: 9815926
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
12
11
2022
pubmed:
25
11
2022
medline:
24
1
2023
entrez:
24
11
2022
Statut:
ppublish
Résumé
In older people living with frailty, polypharmacy can lead to preventable harm like adverse drug reactions and hospitalization. Deprescribing is a strategy to reduce problematic polypharmacy. All stakeholders should be actively involved in developing a person-centred deprescribing process that involves shared decision-making. To co-design an intervention, supported by a logic model, to increase the engagement of older people living with frailty in the process of deprescribing. Experience-based co-design is an approach to service improvement, which uses service users and providers to identify problems and design solutions. This was used to create a person-centred intervention with the potential to improve the quality and outcomes of the deprescribing process. A 'trigger film' showing older people talking about their healthcare experiences was created and facilitated discussions about current problems in the deprescribing process. Problems were then prioritized and appropriate solutions were developed. The review located the solutions in the context of current processes and procedures. An ideal care pathway and a complex intervention to deliver better care were developed. Older people living with frailty, their informal carers and professionals living and/or working in West Yorkshire, England, UK. Deprescribing was considered in the context of primary care. The current deprescribing process differed from an ideal pathway. A complex intervention containing seven elements was required to move towards the ideal pathway. Three of these elements were prototyped and four still need development. The complex intervention responded to priorities about (a) clarity for older people about what was happening at all stages in the deprescribing process and (b) the quality of one-to-one consultations. Priorities for improving the current deprescribing process were successfully identified. Solutions were developed and structured as a complex intervention. Further work is underway to (a) complete the prototyping of the intervention and (b) conduct feasibility testing. Older people living with frailty (and their informal carers) have made a central contribution, as collaborators, to ensure that a complex intervention has the greatest possible potential to enhance the experience of deprescribing medicines.
Sections du résumé
BACKGROUND
In older people living with frailty, polypharmacy can lead to preventable harm like adverse drug reactions and hospitalization. Deprescribing is a strategy to reduce problematic polypharmacy. All stakeholders should be actively involved in developing a person-centred deprescribing process that involves shared decision-making.
OBJECTIVE
To co-design an intervention, supported by a logic model, to increase the engagement of older people living with frailty in the process of deprescribing.
DESIGN
Experience-based co-design is an approach to service improvement, which uses service users and providers to identify problems and design solutions. This was used to create a person-centred intervention with the potential to improve the quality and outcomes of the deprescribing process. A 'trigger film' showing older people talking about their healthcare experiences was created and facilitated discussions about current problems in the deprescribing process. Problems were then prioritized and appropriate solutions were developed. The review located the solutions in the context of current processes and procedures. An ideal care pathway and a complex intervention to deliver better care were developed.
SETTING AND PARTICIPANTS
Older people living with frailty, their informal carers and professionals living and/or working in West Yorkshire, England, UK. Deprescribing was considered in the context of primary care.
RESULTS
The current deprescribing process differed from an ideal pathway. A complex intervention containing seven elements was required to move towards the ideal pathway. Three of these elements were prototyped and four still need development. The complex intervention responded to priorities about (a) clarity for older people about what was happening at all stages in the deprescribing process and (b) the quality of one-to-one consultations.
CONCLUSIONS
Priorities for improving the current deprescribing process were successfully identified. Solutions were developed and structured as a complex intervention. Further work is underway to (a) complete the prototyping of the intervention and (b) conduct feasibility testing.
PATIENT OR PUBLIC CONTRIBUTION
Older people living with frailty (and their informal carers) have made a central contribution, as collaborators, to ensure that a complex intervention has the greatest possible potential to enhance the experience of deprescribing medicines.
Identifiants
pubmed: 36420768
doi: 10.1111/hex.13669
pmc: PMC9854320
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
399-408Subventions
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
© 2022 The Authors. Health Expectations published by John Wiley & Sons Ltd.
Références
Lancet. 2013 Mar 2;381(9868):752-62
pubmed: 23395245
Health Expect. 2023 Feb;26(1):399-408
pubmed: 36420768
Health Expect. 2018 Apr;21(2):539-548
pubmed: 29266797
J Am Med Dir Assoc. 2013 Oct;14(10):761-7
pubmed: 23664484
J Am Pharm Assoc (2003). 2020 Jan - Feb;60(1):105-111
pubmed: 31690514
JAMA Intern Med. 2015 May;175(5):827-34
pubmed: 25798731
J Am Geriatr Soc. 2022 Sep;70(9):2738-2741
pubmed: 35596673
Res Social Adm Pharm. 2021 Dec;17(12):2127-2135
pubmed: 34187746
PLoS One. 2016 Apr 19;11(4):e0151066
pubmed: 27093289
Support Care Cancer. 2012 Nov;20(11):2639-47
pubmed: 22544223
Biomed Pharmacother. 2021 Dec;144:112341
pubmed: 34678725
N Engl J Med. 2003 Apr 17;348(16):1556-64
pubmed: 12700376
Med Humanit. 2019 Sep;45(3):247-257
pubmed: 29954854
BMJ Qual Saf. 2020 Jan;29(1):64-76
pubmed: 31548278
Br J Clin Pharmacol. 2006 Feb;61(2):218-23
pubmed: 16433876
BMJ Open. 2022 Mar 28;12(3):e054279
pubmed: 35351709
BMC Med Res Methodol. 2019 Mar 12;19(1):55
pubmed: 30871474
Can J Hosp Pharm. 2013 May;66(3):201-2
pubmed: 23814291
BMJ Open. 2015 Mar 24;5(3):e006688
pubmed: 25805530
Patient Educ Couns. 2011 Jun;83(3):451-7
pubmed: 21621944
Br J Gen Pract. 2013 Aug;63(613):e543-53
pubmed: 23972195
BMJ Open. 2017 Oct 16;7(10):e016358
pubmed: 29042378
BMJ. 2004 Jul 3;329(7456):15-9
pubmed: 15231615
Age Ageing. 2016 Jan;45(1):115-20
pubmed: 26683048
BMC Fam Pract. 2017 Jun 6;18(1):70
pubmed: 28587644
BMJ. 2021 Sep 30;374:n2061
pubmed: 34593508
Age Ageing. 2016 May;45(3):353-60
pubmed: 26944937
Eur J Hosp Pharm. 2016 Mar;23(2):113-117
pubmed: 31156827
Aust Prescr. 2017 Oct;40(5):174-178
pubmed: 29109600
Med Educ. 1996 Mar;30(2):83-9
pubmed: 8736242
Diabet Med. 2022 Jul;39(7):e14801
pubmed: 35118700
Health Expect. 2020 Jun;23(3):562-570
pubmed: 32045087
Drugs Aging. 2013 Oct;30(10):793-807
pubmed: 23912674
Age Ageing. 2022 Mar 1;51(3):
pubmed: 35353136
Eur J Hosp Pharm. 2017 Jan;24(1):10-15
pubmed: 28184303